Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AllerGen NCE (The Allergy, Genes and Environment Network) was a Canadian non-profit research network dedicated to the causes, treatment, and prevention of allergic diseases and asthma. Established in 2004 through the federal Networks of Centres of Excellence (NCE) program, the organization catalyzed collaborations between academia, industry, and government. Its primary legacy includes the CHILD Cohort Study, a massive longitudinal birth cohort study investigating the origins of allergy and chronic disease. The network supported the development of various diagnostics, therapeutics, and public health policies before concluding its NCE-funded mandate in 2019. Headquartered at McMaster University, it involved over 100 researchers across Canada and significantly advanced the field of immunology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AllerGen NCE.